Silencing of long non-coding RNA PCAT6 restrains gastric cancer cell proliferation and epithelial-mesenchymal transition by targeting microRNA-15a

Dong, Dongfang; Lun, Yue; Sun, Bo; Sun, Hongping; Wang, Qunying; Yuan, Gang; Quan, Jingzi

doi:10.4149/gpb_2019044

Cited by 19 publications

(17 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have confirmed that lncRNA plays a major role in regulating cancer progression by targeting miRNA to regulate mRNA expression (43). For example, Dong et al (44) reported that silencing of PCAT6 restrains cell proliferation and epithelial-mesenchymal transition of gastric cancer cells by targeting miR-15a. Huang et al (16) confirmed that PCAT6 suppresses apoptosis and contributes to cell proliferation by upregulating anti-apoptotic protein apoptosis repressor with caspase recruitment domain via EZH2 in colon cancer.…”

Section: Discussionmentioning

confidence: 99%

lncRNA PCAT6 facilitates cell proliferation and invasion via regulating the miR‑326/hnRNPA2B1 axis in liver cancer

et al. 2021

View full text Add to dashboard Cite

Liver cancer is one of the most common malignant human tumors with the highest morbidity and mortality rates of all cancer types in China. Evidence suggests that long non-coding RNA prostate cancer-associated transcript 6 (PCAT6) plays an essential role in tumor progression. However, the roles and mechanism of PCAT6 in liver cancer remain unclear. The present study showed that the expression of PCAT6 and heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) was upregulated in liver cancer tissues compared with non-cancerous tissues and were associated with poor overall survival time, whereas microRNA (miR)-326 expression was downregulated. Moreover, knockdown of PCAT6 significantly inhibited the proliferation and invasion of liver cancer cells in vitro and in vivo. A dual-luciferase reporter gene assay demonstrated that PCAT6 could bind to miR-326 and that hnRNPA2B1 was a direct target gene of miR-326. Mechanistically, silenced PCAT6 suppressed the malignant phenotype of liver cancer cells through upregulating the inhibitory effect of miR-326 on hnRNPA2B1 expression. Taken together, these data demonstrated that knockdown of PCAT6 inhibited liver cancer progression through regulation of the miR-326/hnRNPA2B1 axis, suggesting that PCAT6 functions as an oncogene and may be a useful biomarker for the future diagnosis and treatment of liver cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

lncRNA PCAT6 facilitates cell proliferation and invasion via regulating the miR‑326/hnRNPA2B1 axis in liver cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…qRT-PCR analysis revealed that the expression levels of PCAT6 were significantly upregulated in 20 GC tissues compared with those in paired adjacent normal tissues. Silencing of PCAT6 significantly restrained the epithelial-mesenchymal transition (EMT) and proliferation of GC cells ( 22 ). PCAT6 expression was also negatively correlated with tumor size, TNM stage, metastasis status, and GC prognosis ( 23 ).…”

Section: The Role Of Pcat6 In Cancer Cellsmentioning

confidence: 99%

“…Several pathways are involved in the carcinogenic effects of PCAT6. For example, silencing of PCAT6 could reduce the protein levels of members of the RB/E2F and Wnt/β-catenin signaling pathways by upregulating miR-15a ( 22 ). PCAT6 can also endogenously compete with miR-30 by targeting MKRN3.…”

Section: The Role Of Pcat6 In Cancer Cellsmentioning

confidence: 99%

The Role of lncRNA PCAT6 in Cancers

Wang

Chen

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Long non-coding RNA (lncRNA) PCAT6 is a member of the Prostate Cancer Associated Transcripts family of molecules. In this review, we focus on the latest studies involving PCAT6 in the diagnosis, treatment, and prognosis of malignant tumors of the digestive, respiratory, urinary, reproductive, motion, and nervous systems. PCAT6 was found to be highly expressed in gastric cancer, colon cancer, hepatocellular carcinoma, lung cancer, bladder cancer, ovarian cancer, breast cancer, cervical cancer, osteosarcoma, glioblastoma, and other tumors. PCAT6 can promote the development and progression of different types of malignant tumors through various mechanisms. Overall, these findings suggest that PCAT6 may play an increasingly vital role in the clinical assessment of these malignant tumors. It can function as an oncogene and may be used as a potential new prognostic biomarker of these tumors.

show abstract

“…Accumulating researches illustrate that in GC, lncRNAs competitively decoy miRNAs via miRNA response elements (MREs), and this process reduces the availability of miRNAs, and indirectly up-regulates the level of downstream mRNAs. [21][22][23] For example, the expression of lncRNA DDX11-AS1 is up-regulated in GC tissues, and functionally, DDX11-AS1 facilitates GC progression by inhibiting miR-873-5p expression. 24 LncRNA FTX expression in GC is also up-regulated, and FTX can promote GC proliferation and invasion by adsorbing miR-144 and up-regulating ZFX; 25 conversely, as a tumor suppressor, lncRNA HAND2-AS1 inhibits the proliferation and migration of GC cells through modulating miR-590-3p/KCNT2 axis.…”

Section: Discussionmentioning

confidence: 99%

<p>LncRNA CTBP1-AS2 Facilitates Gastric Cancer Progression via Regulating the miR-139-3p/MMP11 Axis</p>

Yang

Gao

Liu

et al. 2020

OTT

View full text Add to dashboard Cite

Background This study aimed at probing into the effect of long non-coding RNA (lncRNA) C-terminal binding protein 1 antisense RNA 2 (CTBP1-AS2) on gastric cancer (GC) cell proliferation and apoptosis, and its regulatory function on miR-139-3p and MMP11 . Methods Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to examine the expressions of CTBP1-AS2, miR-139-3p and MMP11 mRNA in GC cell lines and clinical specimens. Cell counting kit-8 (CCK-8) assay, flow cytometry and EdU assay were conducted to examine the effects of CTBP1-AS2 and miR-139-3p on GC cell proliferation and apoptosis. Western blot was applied for detecting the expressions of Bax, Bcl-2 and MMP11 . A lung metastasis mouse model was used to evaluate metastasis of GC cells in vivo. Bioinformatics, dual-luciferase report assay, RIP and RNA pull-down assays were utilized to validate the targeted relationship between CTBP1-AS2 and miR-139-3p as well as the targeting relationship between miR-139-3p and MMP11 . Results CTBP1-AS2 was highly expressed in GC, and its high expression was strongly associated with increased TNM stage, increased tumor size and low degree of differentiation of the tumor tissues. Meanwhile, CTBP1-AS2 promoted GC cell proliferation, metastasis and suppressed apoptosis, while miR-139-3p could weaken these effects. In addition, CTBP1-AS2 was identified as a molecular sponge for miR-139-3p, and MMP11 was verified as a target gene of CTBP1-AS2. CTBP1-AS2 could increase the expression of MMP11 via repressing miR-139-3p. Conclusion CTBP1-AS2 promotes GC cells and inhibits apoptosis by regulating the miR-139-3p/ MMP11 molecular axis.

show abstract

Silencing of long non-coding RNA PCAT6 restrains gastric cancer cell proliferation and epithelial-mesenchymal transition by targeting microRNA-15a

Cited by 19 publications

References 41 publications

lncRNA PCAT6 facilitates cell proliferation and invasion via regulating the miR‑326/hnRNPA2B1 axis in liver cancer

lncRNA PCAT6 facilitates cell proliferation and invasion via regulating the miR‑326/hnRNPA2B1 axis in liver cancer

The Role of lncRNA PCAT6 in Cancers

<p>LncRNA CTBP1-AS2 Facilitates Gastric Cancer Progression via Regulating the miR-139-3p/MMP11 Axis</p>

Contact Info

Product

Resources

About